Key result
The UA/HDL-C ratio was strongly associated with fatty liver disease in a sex-adjusted model (coefficient 3.47, p<0.001), demonstrating its potential as an early biomarker.
Why the study?
Fatty liver disease is asymptomatic early and linked to cardiovascular risk, warranting evaluation of serum uric acid to HDL cholesterol ratio as a biomarker compared to established indices.
Is the serum uric acid to HDL cholesterol ratio (UA/HDL-C) a reliable surrogate marker for fatty liver disease compared to established metabolic scores in adults?
Cross-Sectional (n=1,470)
Is the serum uric acid to HDL cholesterol ratio (UA/HDL-C) a reliable surrogate marker for fatty liver disease compared to established metabolic scores in adults?
Effect estimate: coefficient 3.47
p-value: p=<0.001
The UA/HDL-C ratio is strongly associated with fatty liver disease and may serve as a practical, early biomarker for identifying at-risk patients.
No takes yet. Share an insight, caveat, or question.
UA/HDL-C may aid early FLD detection in cardiometabolic patients; leaves open superiority over established indices.
Posadas‐Sánchez et al. (2025) conducted a cross-sectional in Fatty liver disease (FLD) (n=1,470). Serum uric acid to HDL cholesterol ratio (UA/HDL-C) was evaluated on Fatty liver disease (FLD) diagnosed by non-contrast computed tomography (coefficient 3.47, p=<0.001). The UA/HDL-C ratio was strongly associated with fatty liver disease in a sex-adjusted model (coefficient 3.47, p<0.001), demonstrating its potential as an early biomarker.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: